Nuclear emission-based imaging in the study of brain function

Nuclear emission - based imaging has been used in medicine for decades either in the form of Single Photon Emission Computerized Tomography (SPECT) or Positron Emission Tomography (PET). Both techniques are based on radiolabelling molecules of biological interest (radiotracers) with either a gamma (SPECT) or a positron (PET) emitting radionuclide. By detecting radiation from the radiolabels and reconstructing the acquired data it is possible to form an image of the radiotracer distribution in the body and thus obtain information on the biological process that the radiotracer is tagging. While most of the clinical applications of PET are in oncology, where the glucose analogue $^{\mathrm{18}}$F-flurodeoxyglocose (FDG) is the most commonly used radiotracer, the importance of PET imaging for brain applications is rapidly increasing. Numerous radiotracers exist that can tag different neurotransmitter systems as well as abnormal protein aggregations that are known to underlie several brain diseases: amyloid deposition, a characteristic of Alzheimer's, and, more recently, tau deposition, which is deemed abnormal not only in dementia, but also in Parkinson's syndrome and traumatic brain injury. Imaging has shown that may brain diseases start decades before clinical symptoms, in part explaining the difficulty of developing adequate treatments. This talk will briefly summarize the role of PET imaging in the study of neurodegeneration and discuss the upcoming hybrid PET/MRI imaging instrumentation.